Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
暂无分享,去创建一个
P. Gaulard | G. Salles | B. Coiffier | R. Bouabdallah | P. Feugier | H. Tilly | C. Gisselbrecht | C. Sebban | É. Lepage | F. Reyes | P. Solal-Céligny | B. Christian | F. Morschhauser | A. Bosly | A. Hoof | C. Fermé | A. van Hoof | Bertrand Coiffier | Eric Lepage | Christophe Fermé | André Bosly | A. Van Hoof | Catherine Sebban | Bernard Christian | Philippe Gaulard | Gilles Salles
[1] R. Gascoyne,et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] W. Hiddemann,et al. Combined immuno-chemotherapy (R-FCM) results in superior remission rates and overall survival in recurrent follicular and mantle cell lymphoma: Follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) , 2005 .
[3] R. Marcus,et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. , 2005, Blood.
[4] B. Coiffier. Treatment of diffuse large B-cell lymphoma. , 2005, Current hematology reports.
[5] Hervé Watier,et al. From the bench to the bedside: ways to improve rituximab efficacy. , 2004, Blood.
[6] Dirk Hasenclever,et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. , 2004, Blood.
[7] M. Pfreundschuh,et al. Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -early stopping after the first interim analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. Cragg,et al. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. , 2004, Blood.
[9] B. Coiffier. Effective Immunochemotherapy For Aggressive Non-Hodgkin's Lymphoma. , 2004, Seminars in oncology.
[10] B. Coiffier. Dose intensity or monoclonal antibody in first-line treatment. , 2004, The hematology journal : the official journal of the European Haematology Association.
[11] T. Molina,et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. , 2003, Blood.
[12] M. Caligiuri,et al. Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma? , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] Mitchell R. Smith. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance , 2003, Oncogene.
[14] B. Coiffier. Increasing chemotherapy intensity in aggressive lymphomas: a renewal? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] D. Hossfeld. E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .
[16] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[17] W. Wilson,et al. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. , 2002, Seminars in oncology.
[18] J. Vose,et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] P. Gaulard,et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] J. Armitage,et al. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Armitage,et al. International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] V. Diehl,et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. , 1998, Blood.
[24] A. Hagenbeek,et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.
[25] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[26] T M Grogan,et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[27] R. Duquesne. Centre hospitalier de Lens. , 1957 .